

## Human amniotic epithelium (HAE) as a possible source of stem cells (SC)

Guadalupe García-López<sup>1</sup>, Irma Lydia García-Castro<sup>1</sup>, Daniela Ávila-González<sup>1</sup>, Anayansi Molina-Hernández<sup>1</sup>, Héctor Flores-Herrera<sup>2</sup>, Horacio Merchant-Larios<sup>3</sup> and Fabián Díaz-Martínez<sup>1\*</sup>

<sup>1</sup>Department of Cellular Biology, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, México, D.F.; <sup>2</sup>Department of Biochemistry and Celular Biology, Instituto Nacional de Perinatología Isidro Espinosa de los Reyes, México, D.F.; <sup>3</sup>Department of Celular Biology and Physiology, Institute of Biomedical Research, Universidad Nacional Autónoma de México, México, D.F.

### Abstract

There have been major recent advances in the field of developmental biology due to the investigation on stem cells (SC). Stem cells are characterized by their capacity of auto-renewal and differentiation to different cellular phenotypes. Based on the developmental stage, they can be classified into two different types: embryonic SCs and adult SCs. It has been widely reported that several problems need to be resolved before their possible clinical applications. As a result, fetal membranes have been suggested as an alternative source of SCs. In the human amniotic epithelium, the presence of markers of pluripotent SC's has been reported, and its capacity as a feeder layer for expansion of different SC types. Also, fetal membranes are a discarded product after delivery, and thus there are not any ethical issues related to its use. In conclusion, the human amniotic epithelium can be a strong candidate for regenerative medicine. (Gac Med Mex. 2015;151:61-8)

**Corresponding author:** Fabián Díaz Martínez, nfdiaz00@yahoo.com.mx

**KEY WORDS:** Stem cells. Human fetal membranes. Human amniotic epithelium cells.

### Introduction

Research on embryonic stem cells (ESCs) has importantly contributed to the recent advance in the fields of developmental and cell biology. Also, due to their wide differentiation capability, this type of cells have raised interest on and kept the promise of their possible use in cell-replacement therapies. However, there are serious problems that remain to be solved before translating ESCs use from basic to clinical research. An example of such a problem is their probability to

form tumors when these cells are grafted in an undifferentiated stage<sup>1</sup>, as well as the ethical issues their derivation entails<sup>2</sup>. Likewise, the use of adult stem cells (ASCs), obtained from tissues of adult organisms, e.g. bone marrow, brain, or muscles, has been suggested. Although these cells have been studied, their extraction is difficult and their obtained number is insufficient for use in cell-replacement therapies. Additionally, ASCs show limited proliferation and plasticity compared with ESCs<sup>3</sup>, which reveals the need of alternative SC sources, such as the human amniotic epithelial cells (hAECs)<sup>4,5</sup>, since they show a series of unique features<sup>6</sup>. Therefore, this paper focuses on hAECs as a possible source of SCs and hAEC potential use in this interesting research area.

#### Correspondence:

\*Fabián Díaz Martínez  
Departamento de Biología Celular  
Instituto Nacional de Perinatología  
Montes Urales, 800  
Col. Lomas Virreyes, Del. Miguel Hidalgo, C.P. 11000, México, D.F.  
E-mail: nfdiaz00@yahoo.com.mx

Date of reception: 22-07-2013

Date of acceptance: 19-05-2014

**Table 1. Stem cells classification based on their differentiation potential**

| Classification | Differentiation potential                                                                                                                                              |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Totipotent     | Capability to form all lineages of the organism; in mammals, only the zygote is totipotent                                                                             |
| Pluripotent    | Capability to form all the embryo lineages, including germ cells; for example, ESCs                                                                                    |
| Multipotent    | Potential to form cells restricted to an embryonic layer in particular; for example, neural SC, which will differentiate into neurons, astrocytes and oligodendrocytes |
| Unipotent      | Cells that form a single specific cell type; for example, epithelial SC                                                                                                |

Modified from Jaenisch et al.<sup>68</sup>

## SCs

SCs are characterized by their dedifferentiation and potential to auto-renew and differentiate into a variety of specialized cell types. SCs are present in several tissues during embryonic stages as well as in adult animals, and can be classified according to their differentiation potential (Table 1).

On the other hand, the classification based on their developmental stage at isolation assort SCs as ESCs or ASCs.

## ESCs

In 1981, the Martin Evans and Gail Martin groups isolated pluripotent cell lines from the blastocysts of mouse pre-implantation for the first time, and named them embryonic stem cells (ESCs)<sup>7,8</sup>. Derivation of these cells was achieved growing the inner cell mass of the blastocyst on a mouse embryonic fibroblast (MEF) feeder layer of 14 days of gestational age. The fibroblasts secreted soluble factors that allowed for cells of the inner cell mass to be preserved *in vitro* at a pluripotent stage, thus allowing the obtainment of these cell lines. Mouse-derived ESCs are currently among the most widely studied SCs and are characterized by presenting large nuclei and small cytoplasm, growing in compact colonies, having high telomerase activity (telomerase is associated with the capability for cell proliferation, protection and chromosome stabilization)<sup>9</sup>, and showing a normal karyotype

(i.e., only a small proportion present chromosomal abnormalities). Furthermore, these cells can be preserved *in vitro* without an apparent loss of their self-renewal and differentiation capabilities. ESCs express molecular markers such as the tissue-unspecific alkaline phosphatase (an enzyme also present in germ line cells), transcriptional regulatory factors that maintain the cells in an undifferentiated state (octamer-binding transcription factor 4 [Oct-4], sex-determining region Y (SRY)-box 2 [Sox2] and Nanog) and transmembrane proteins (stage-specific embryonic antigen [SSEA-1], tumor rejection antigen [TRA-1-60]). This way, preserved in conditions that favor their pluripotent status, these cells do not present morphological or molecular characteristics of differentiated cells.

With procedures similar to those used to derive mouse ESCs, the group of Thompson generated non-human primate (Rhesus monkey)<sup>10</sup> and, later, human ESCs. In 1988, they reported the isolation and culture of five human embryonic stem cell (hESC) lines obtained from embryos of less than a gestational week coming from *in vitro* fertilization clinics and donated by parents for this specific purpose. As a result, when cultured *in vitro*, rounded with well-defined edges, compact and flat colonies, with cells presenting a prominent nucleus and a high nucleus-cytoplasm ratio and that maintained an unlimited proliferation capability, were obtained<sup>11</sup>.

Once an ESC line is obtained, its pluripotent state must be verified by means of a series of laboratory tests. In cells obtained from mouse, its pluripotency can be demonstrated by injecting ESCs into blastocysts of the same species and observing their contribution to every tissue of the animal, spermatozooids and oocytes included<sup>12</sup>. Thus, chimeric organisms with a functional germ line are obtained<sup>13</sup>. Pluripotent state has also been demonstrated by means of tetraploid complementation, through the production of 4n blastocysts by cell fusion and ESCs introduction to the blastocyst. Since 4n cells are not able to produce somatic cells, the resulting organisms are entirely formed by ESC derivatives<sup>14</sup>. A third form to test the ESC pluripotent capability is by forming differentiated cells *in vitro*, either directly or indirectly. The first method consists in removing the signals that allow for self-renewal; consequently, cells differentiate spontaneously. In the second method, the differentiation protocols allow cell exposure to specific culture conditions and growth factors to induce them into a particular cell lineage<sup>15</sup>.

In the case of the hESCs, ethical issues prevent the production of chimeric animals or tetraploid comple-

mentation. Therefore, the highest standard of evidence is the formation of teratomas (tumors with ectoderm, endoderm and mesoderm cell lineages) by injecting the hESC into immunodeficient mice<sup>16</sup>, and the demonstration that cells are able to differentiate *in vitro* into tissues of the three embryonic layers. The recognition of the ESC identity has been achieved by using the above mentioned tests together with molecular markers (Oct-4, Sox-2, Nanog and alkaline phosphatase) and surface antigens exclusive to this cell type (SSEA-3, SSEA-4, TRA-1-60 and TRA-1-18). However, research with hESC entails ethical and political controversies to be solved before its inclusion in clinical research<sup>2</sup>.

Other types of pluripotent cells, such as epiblast SC and induced pluripotent stem cells (iPSC), have also been described. However, due to space limitations, we will not review them in detail. We refer the reader to the works published by Chenoweth et al.<sup>17</sup>, Stadtfeld et al.<sup>18</sup>, Teoh et al.<sup>19</sup> and Wu et al.<sup>20</sup>.

## ASCs

SCs from adult tissue are embedded in tissue and organ differentiated cells, and their main role is to maintain and repair their niches. These niches represent a specialized tissue microenvironment where SCs establish complex and reciprocal interactions with supporting cells and the extracellular matrix through adherent unions mediated by cadherins, catenins, integrins and selectins and their ligands, adhesion molecules, growth factor and chemokines receptors, etc.<sup>21</sup>. ASCs have also a role in the secretion of various soluble factors functioning as non-adhesion-mediated cell interaction mechanisms (Wnt/frizzled, Notch/Delta-Jagged) that contribute to their restricted mobility and adoption of either a quiescent or an active state within their niche<sup>22,23</sup>.

These SCs are usually multipotent, since they have certain compromise to form cells of the same cell type of the tissue embedding them. This cell type has been identified in several organs, such as brain, bone marrow, skeletal muscle, skin, intestine, etc. Though, the ASCs number is very limited, they are difficult to find and isolate, and their differentiation range is restricted to the cell type of their niche, as previously mentioned<sup>24,25</sup>.

Due to the above-mentioned disadvantages associated to the obtainment and use of both, hESC and ASC, alternative sources like the human extra-embryonic tissues have been examined.


## Human extra-embryonic tissues

The extra-embryonic tissues comprise the placenta, umbilical cord and fetal membranes. A term placenta weighs between 400 and 600 g<sup>26</sup>, and has a discoid shape, with a 15-20 cm diameter and 2-3 cm thickness. It has two sides: the first known as chorionic plate has a fetal origin, faces the amniotic cavity, and is formed by the amnion and the chorion; the other side, is named basal plate, is formed by the decidua (basal and parietal), and has a maternal origin<sup>27,28</sup>. The placenta acts as a mother-fetus interphase, involved in gas, nutrients and waste products exchange. It also works as an endocrine organ producing hormones and growth factors that regulate both fetal growth and maternal physiology<sup>29</sup>. The umbilical cord consists of a connective mucous tissue known as Warthon's jelly that extends along the amniotic epithelium and covers the umbilical vessels. Its main function is to prevent vessel compression, torsion or flexion, to allow the bi-directional blood flow between maternal and fetal circulation that the vessels provide<sup>30</sup>. Finally, fetal membranes are formed by two attached membranes, the amnion and the chorion (Fig. 1).

## Human fetal membranes

The amniotic membrane is a translucent biological membrane without nerves, muscles or lymphatic vessels. The amnion thickness ranges from 0.02 to 0.5 mm and consists of three histological layers: epithelial layer, basal layer and avascular mesenchymal tissue. The inner layer, adjacent to the amniotic fluid, is formed by a homogeneous mantle of cuboidal cells firmly attached to the basal membrane, which, in turn, is attached to an acellular layer composed by collagen, types I, II and V. A stromal cell lining composed of fibroblasts and scarce macrophages embedded in a reticular-fiber mesh covers this layer externally. The most external, intermediate or spongy layer considerably varies in thickness, and is rich in elastin, hydrated proteoglycans (especially perlecan), glycoproteins and type III collagen fibers that separate amnion from chorion. The chorion is the thickest histological structure among the fetal membranes and holds more cellularity than the amnion. The final part of the chorion is interlocked with the uterine decidua.

Particularly, hAECs display microvilli on their apical surface and perform an intra- and trans-cellular secretory function. Additionally, it has been described a large irregular nucleus with intra-cytoplasmic organelles



**Figure 1.** Semifine cross-section (1  $\mu\text{m}$ ) of a 40-gestational-week human fetal membrane obtained from elective cesarean, included in EPON and stained with 0.5% toluidine blue. The image shows the two fetal-membrane constitutive regions: amnion and chorion (20X) (modified from the Guadalupe García Gómez Masters Degree thesis, UNAM, 2007).

and pinocytic vesicles. One of the hAECs basic functions is to provide the developing embryo with an environment to be suspended, where the embryo will be able grow free of the pressure exerted by structures surrounding its body and protected against desiccation. In addition, multiple metabolic functions, such as water and soluble material transportation and production of factors without a specific biologic function, including vasoactive peptides, growth factors and cytokines, have been described<sup>31</sup>. Interestingly, presence of SCs among hAECs has been suggested, as described later.

### Embryonic development of human amniotic epithelium

Unlike other structures forming the placenta, the amnion is generated around the 8<sup>th</sup> day after fertilization, before gastrulation. In this period, the blastocyst is implanted in the endometrial stroma and the inner cell mass is differentiated into two layers: one composed by cuboidal cells (hypoblast) and other of cylindrical cells (epiblast). The three embryonic cell layers that make up the embryo originate in the epiblast, whereas the hypoblast generates the extra-embryonic endoderm<sup>32</sup>. Within the epiblast, a small cavity (the amniotic cavity)

appears, and the adjacent cells (amnioblasts) form the amniotic epithelium. The development of the amnion from the epiblast is very important, since this tissue has been suggested to contain a SC population<sup>5,33</sup>.

### In vitro derivation and preservation of hAECs

Different hAEC *in vitro*-derivation protocols have been reported. These cells are usually obtained from 38-to-39-gestational-week term placentas by means of elective cesarean section, after informed consent is obtained. It is important pointing out that women must not be in labor or have premature membrane rupture, chorioamnionitis or chromosomal abnormalities for tissue donation. hAEC-isolation protocols consist in mechanically detaching the amniotic membrane from the chorion, washing it with a buffering solution, then incubating it at 37 °C with trypsin at different times and different concentrations<sup>5,34-40</sup> or using dispase 1.2 U/ml and scraping the tissue to remove the cells<sup>35</sup>. Once the hAECs are obtained, they are cultured at different densities per cm<sup>2</sup> ranging from  $6 \times 10^4$  to  $1 \times 10^5$ , in supplemented Dulbecco's Modified Eagle's Medium (DMEM) and in the presence of epidermal growth factor (EGF) at a 10 ng/ml concentration<sup>37,41,42</sup>. It is worth

mentioning that the composition of this medium is very similar to the one used in ESC<sup>43,44</sup>.

Finally, derivation of hAEC in xenocontaminant-free medium (free of animal derivatives) has been reported, thinking on its possible application in the clinic. This way, modified reagents have been employed, which include Trypzean as digestion solution (it does not contain contaminants traditionally found in bovine or porcine trypsin) and EpiLife medium (serum-free basal medium)<sup>45</sup>.

## Molecular and cell-surface markers found in hAECs

When stained with hematoxylin-eosine *in vitro*, hAECs present an homogeneous appearance<sup>37,46</sup>, but express a heterogeneous phenotype when membrane markers are determined, with different antigenic expression degrees. These findings would indicate the presence of cell subpopulations, probably SCs in conjunction with more differentiated cells. This way, the cells express a large variety of surface antigens (Table 2).

Interestingly, they express ESC-associated molecular markers such as Oct-4, Sox-2, Nanog, reduced expression 1 (Rex-1), fibroblast growth factor-4 (FGF-4), cryptic family 1 (CFC-1), developmental pluripotency-associated protein 3 (DPPA-3) and c-kit<sup>5,35,37,47</sup>. These transcription factors play an important role to maintain the pluripotent state of the cells, through complex networks between them<sup>48,49</sup>. In addition, *in vitro* cultured hAECs have been reported to be tissue non-specific alkaline phosphatase-positive (ESC marker)<sup>35</sup>. Finally, hAECs have been shown to express low or moderate levels of the polymorphic antigens HLA A-B-C (class Ia), lack HLADR (class II)<sup>41</sup> and express HLA-G<sup>50</sup>, data that can explain the low immunogenic of the human amniotic membrane and the absence of rejection when it is transplanted<sup>51,52</sup>.

Additionally, when cultured *in vitro*, hAECs express markers specific to each embryonic layer. Regarding the ectoderm, nestin, microtubule-associated protein (MAP-2), intermediate neurofilament protein, glial fibrillary acidic protein (GFAP) and neuron-specific enolase have been identified<sup>37</sup>. Endoderm markers are: globin transcription factor (GATA) binding protein 4 (GATA-4), hepatocyte nuclear factor 3b (HNF-3b),  $\alpha$ -fetoprotein and glucose transporter (GLUT-2). Finally, mesoderm markers are: atrial natriuretic peptide, heavy and light chain myosin, actin, etc., all of them associated with the cardiomyocytic lineage<sup>37</sup>. Together, these data

**Table 2. Expression of surface antigens present in the hAECs**

| Reference                      | Antigen in hAEC                                                                                                                                                                                         |
|--------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Miki et al. <sup>37</sup>      | CCR-4, CD117 (c-kit), CD24, CD324                                                                                                                                                                       |
| Raisanen et al. <sup>69</sup>  | (e-cadherin), CD338 (ABCG-2), CD49f, CD54 (ICAM-1), CD9, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81                                                                                                             |
| Ilancheran et al. <sup>5</sup> | CD90, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81                                                                                                                                                                |
| Minas et al. <sup>70</sup>     | GCTM-2, SSEA-4                                                                                                                                                                                          |
| Parolini et al. <sup>71</sup>  | CD10, DC105, CD117 (c-kit), CD13, CD140b, CD166 (ALCAM), CD29, CD324 (E-cadherin), CD44, CD49e, CD73, CD90, GTM-2, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81                                                   |
| Banas et al. <sup>72</sup>     | c-met, CD24, CD29, CD324 (E-cadherin), CD338 (ABCG-2), CD9, SSEA-3, SSEA-4, TRA-1-60, TRA-1-81                                                                                                          |
| Stadler et al. <sup>73</sup>   | CD54 (ICAM-1)                                                                                                                                                                                           |
| Bilic et al. <sup>35</sup>     | CD166 (ALCAM), CD44, CD49d, CD73, SSEA-3, SSEA-4                                                                                                                                                        |
| Fatimah et al. <sup>74</sup>   | CD44, CD73, CD9                                                                                                                                                                                         |
| Murphy et al. <sup>45</sup>    | CD1b, CD10, CD26, CD29, CD34, CD45, CD46, CD55, CD58, CD29, CD63, CD73, CD77, CD81, CD90, CD91, CD95, CD98, CD104, CD108, CD109, CD142, CD147, CD151, CD164, CD166, CD227, EGFR, fil-R, HLA-ABC, HLA-DQ |
| Pratama et al. <sup>41</sup>   | E-cadherin, CD49f, CK7, EpCAM, vimentin, CD44, CD105, CD90, CD146, CD29, HLA-ABC, CD40                                                                                                                  |
| Maguire et al. <sup>75</sup>   | SSEA-1, SSEA-4, TRA-1-60, TRA-1-81                                                                                                                                                                      |

CCR-4: chemokine receptor type 4; CD: cluster of differentiation; GCTM-2: germ cell tumor marker; CK7: cytokeratine 7; EGFR: epidermal growth factor receptor; HLA: human leukocyte antigen.

suggest a pluripotent state as well as a wide heterogeneity of the hAECs.

## Pluripotency tests in hAECs

As previously mentioned, there is a series of laboratory tests to demonstrate the pluripotent state of the SCs. In the case of hAECs, Tamagawa et al., in 2004, were the first to describe their pluripotent features, by creating xenogenic chimeres *in vitro* from cells isolated from human amnion with mouse embryonic cells, and demonstrating the contribution of hAECs to the



**Table 3. hAEC *in vitro* differentiation into specialized cells of the three embryonic layers**

| Reference                      | Lineage                                                        |                                                        |                             |
|--------------------------------|----------------------------------------------------------------|--------------------------------------------------------|-----------------------------|
|                                | Endoderm                                                       | Mesoderm                                               | Ectoderm                    |
| Miki et al. <sup>37</sup>      | Pancreatic cells                                               | Cardiomyocytes                                         | Neural cells                |
| Ilancheran et al. <sup>5</sup> | Pancreatic cells<br>Hepatic cells                              | Myocytes<br>Osteocytes<br>Adipocytes<br>Cardiomyocytes | Neural cells                |
| Kim et al. <sup>36</sup>       | –                                                              | Adipocytes<br>Osteocytes<br>Condrocytes                | Neural cells                |
| Bilic et al. <sup>35</sup>     | –                                                              | Osteocytes<br>Myocytes<br>Adipocytes                   | –                           |
| Murphy et al. <sup>45</sup>    | Pulmonary epithelium cells                                     | Osteocytes<br>Adipocytes                               | Neural cells<br>Glial cells |
| Pratama et al. <sup>41</sup>   | Alveolar epithelium cells<br>Pancreatic cells<br>Hepatic cells | Osteocytes<br>Condrocytes                              | –                           |
| Marongiu et al. <sup>76</sup>  | Hepatic cells                                                  | –                                                      | –                           |
| Fant et al. <sup>77</sup>      | –                                                              | Cardiomyocytes                                         | –                           |

formation of all three germ layers (endoderm, ectoderm and mesoderm) through the formation of embryoid bodies<sup>53</sup>.

The capability of hAECs to form clonal colonies (a property of ESCs) in low-density cultures (30-50 cells per cm<sup>2</sup>) has also been reported<sup>5,41</sup>. However, and in contrast to hESCs, these cells are not capable of forming teratomas: when being inoculated at a  $5 \times 10^5$  cell-density in testicles of immunodeficient mouse, no formation of tumors was reported after 10 weeks<sup>5</sup>. Miki et al. injected hAEC at  $1 \times 10^6$  into the liver and rear legs of mice with severe combined immunodeficiency (SCID); the animals were examined at 7 months looking for any evidence of tumor growth, but the authors did not report any finding<sup>37</sup>. These data demonstrate that, when being injected to immunodeficient mice, hAECs are unable to form teratomas, a property that would be very useful in the clinical setting, since one of the biggest problems with the use of hESCs is the possible development of teratomas when being transplanted in undifferentiated state.

In spite of the loss of teratoma formation, hAECs have been differentiated *in vitro* into endoderm, mesoderm and ectoderm derivatives (Table 3). The techniques used to perform the phenotype determination involved polymerase chain reaction (PCR) and immunocytochemistry.

### hAECs as a feeder layer of pluripotent cells

hAECs, as opposed to hESCs, do not require a second cell type as a feeder layer for their growth. They adhere to plastic and to flasks covered with basement membrane or other materials in conventional media, as previously mentioned. However, they have been proposed as a substitute niche for the preservation of SCs of different origins<sup>54</sup>. This way, limbal epithelial cells<sup>55</sup>, epiblast-derived SCs (EpiSC)<sup>56</sup>, iPSC<sup>57,58</sup> and spermatogonial stem cells (SGSC)<sup>59</sup> have been shown to be successfully cultured using hAEC as culture substrate. In the particular case of SGSCs, the expression of Nanog and Oct-4 is higher in cells cultured in hAEC than in those cultured in MEF or with other cell type<sup>60</sup>. Furthermore, Lai's group used hAEC to maintain the undifferentiated state of murine ESC, and reported that the ESCs expressed 3-5 times more FGF, Oct-4, Nanog, Sox-2 and Rex-1, than cells cultured in MEF, using the reverse transcription technique followed by real-time polymerase chain reaction (RT-PCR). The authors suggested that these effects might be caused by production of leukemia inhibitory factor (LIF)<sup>61</sup>. On the other hand, Liu et al. reported having obtained human iPSC on hAEC, an effect mediated by micro RNA 145 when the levels of Sox-2 were increased in the reprogrammed cells<sup>57</sup>.

## Anti-inflammatory, anti-microbial and low-immune-response properties of amniotic cells

Amnion-derived cells have been considered an ideal tissue for allogeneic transplantation, based on their anti-inflammatory and low immune response effects. hAECs have been reported to express several anti-angiogenic markers and anti-inflammatory proteins including the interleukin 1 receptor-agonist, metalloproteases 1, 2, 3, 4 and 5 inhibitors and interleukin 10<sup>62</sup>. In addition, they suppress the tumor growth factor b isoforms and its type II receptor, which triggers collagen deposit in the site of lesion and fibrosis<sup>63</sup>.

Beta defensins have also been described to be a group of antimicrobial peptides secreted by epithelial cells of the mucosae and the amnion, which are integral part of the innate immune system<sup>64</sup>.

With regard to low immune response, no rejection signs have been reported when the amniotic membrane has been grafted in healthy volunteers without underlying diseases<sup>65</sup>. On the other hand, amnion cells express the non-polymorphic antigen HLA-G, but they lack polymorphic antigens HLA-A (class A) and HLA-DR (class B)<sup>66</sup>. This characteristic confers them an immune advantage by decreasing the risk of rejection when being transplanted.

The human amniotic membrane is an inexpensive biological source of matrix for cell culture. Additionally, expression of several growth factors and cytokines (EGF, keratinocyte growth factor [KGF], hepatocyte growth factor [HGF], basic fibroblastic growth factor [bFGF], TGF- $\alpha$ , transforming growth factor- $\beta$  [TGF- $\beta$ ], bone morphogenetic growth protein-4 [BMP-4], etc.) has been described<sup>67</sup>.

## Conclusions

The information here presented suggests that hAECs have similar characteristics to pluripotent SCs, which makes them excellent candidates to be used for cell-replacement therapies. In addition, hAEC derivation does not entail ethical issues, these cells do not form teratomas when transplanted at an undifferentiated state, do not present immune response and have anti-inflammatory and antimicrobial properties. Nevertheless, further investigation to enable their characterization is required since hAECs form heterogeneous populations, and the reported protocols for their isolation are diverse.

## Acknowledgements

The present work was supported by CONACYT (140917 and 130627) and INPER (212250-21041 and 212250-21081), granted to Fabián Díaz-Martínez. Irma Lydia García-Castro (213945) and Daniela Ávila-González (231731) are CONACYT scholarship.

Guadalupe García-López is a student of the Doctorate in Biomedical Sciences Program at UNAM. We are thankful to Dr. Federico Martínez-Montes and Dr. Héctor Mayani-Viveros for their valuable review and suggestions on this work, which contributed to enhance its quality.

## References

1. Kuroda T, Yasuda S, Sato Y. Tumorigenicity studies for human pluripotent stem cell-derived products. *Biol Pharm Bull.* 2013;36(2): 189-92.
2. Lo B, Parham L. Ethical issues in stem cell research. *Endocr Rev.* 2009;30(3):204-13.
3. Wagner W, Wein F, Seckinger A, et al. Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. *Exp Hematol.* 2005;33(11):1402-16.
4. Evangelista M, Soncini M, Parolini O. Placenta-derived stem cells: new hope for cell therapy? *Cytotechnology.* 2008;58(1):33-42.
5. Ilancheran S, Michalska A, Peh G, Wallace EM, Pera M, Manuelpillai U. Stem cells derived from human fetal membranes display multilineage differentiation potential. *Biol Reprod.* 2007;77(3):577-88.
6. Chen CP, Liu SH, Huang JP, et al. Engraftment potential of human placenta-derived mesenchymal stem cells after in utero transplantation in rats. *Hum Reprod.* 2009;24(1):154-65.
7. Evans MJ, Kaufman MH. Establishment in culture of pluripotent cells from mouse embryos. *Nature.* 1981;292(5819):154-6.
8. Martin GR. Isolation of a pluripotent cell line from early mouse embryos cultured in medium conditioned by teratocarcinoma stem cells. *Proc Natl Acad Sci U S A.* 1981;78(12):7634-8.
9. Pereira Fde A, Tavares RL, Camargos AF, da Silva Filho AL. Telomerase activity alterations in sequential passages of mouse embryonic stem cells. *Cell Biol Int.* 2012;36(8):755-7.
10. Thomson JA, Kalishman J, Golos TG, et al. Isolation of a primate embryonic stem cell line. *Proc Natl Acad Sci U S A.* 1995;92(17):7844-8.
11. Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. *Science.* 1998;282(5391):1145-7.
12. Bradley A, Evans M, Kaufman MH, Robertson E. Formation of germ-line chimaeras from embryo-derived teratocarcinoma cell lines. *Nature.* 1984;309(5965):255-6.
13. Artus J, Hadjantonakis AK. Generation of chimeras by aggregation of embryonic stem cells with diploid or tetraploid mouse embryos. *Methods Mol Biol.* 2011;693:37-56.
14. Lin CJ, Amano T, Zhang J, Chen YE, Tian XC. Acceptance of embryonic stem cells by a wide developmental range of mouse tetraploid embryos. *Biol Reprod.* 2010;83(2):177-84.
15. Trounson A. The production and directed differentiation of human embryonic stem cells. *Endocr Rev.* 2006;27(2):208-19.
16. Hanna JH, Saha K, Jaenisch R. Pluripotency and cellular reprogramming: facts, hypotheses, unresolved issues. *Cell.* 2010;143(4):508-25.
17. Chenoweth JG, McKay RD, Tesar PJ. Epiblast stem cells contribute new insight into pluripotency and gastrulation. *Dev Growth Differ.* 2010;52(3):293-301.
18. Stadtfeld M, Hochedlinger K. Induced pluripotency: history, mechanisms, and applications. *Genes Dev.* 2010;24(20):2239-63.
19. Teoh HK, Cheong SK. Induced pluripotent stem cells in research and therapy. *Malays J Pathol.* 2012;34(1):1-13.
20. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. *Nat Cell Biol.* 2011;13(5):497-505.
21. Zhang J, Li L. Stem cell niche: microenvironment and beyond. *J Biol Chem.* 2008;283(15):9499-503.
22. Gurtner GC, Callaghan MJ, Longaker MT. Progress and potential for regenerative medicine. *Annu Rev Med.* 2007;58:299-312.
23. Weissman IL. Stem cells: units of development, units of regeneration, and units in evolution. *Cell.* 2000;100(1):157-68.
24. Luu HH, Song WX, Luo X, et al. Distinct roles of bone morphogenetic proteins in osteogenic differentiation of mesenchymal stem cells. *J Orthop Res.* 2007;25(5):665-77.

25. Friedenstein AJ, Petrakova KV, Kurolesova AI, Frolova GP. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. *Transplantation*. 1968;6(2):230-47.
26. López-Cruz G M-RJ, Gaván-Espinosa H, Sosa-Vásquez J, Reyes-Hernández U. Estudio de la placenta. I. Correlación: Peso del recién nacido y peso placentario. *Bol Clin Hosp Infant Edo Son*. 2009;26(1):8-12.
27. Bourne G. The foetal membranes. A review of the anatomy of normal amnion and chorion and some aspects of their function. *Postgrad Med J*. 1962;38:193-201.
28. Benirschke K KP. *Anatomy and Pathology of the placental membranes*. En: *Pathology of the human Placenta*. 4.ª ed. Nueva York; 2000. p. 281334.
29. Fu G, Brkic J, Hayder H, Peng C. MicroRNAs in Human Placental Development and Pregnancy Complications. *Int J Mol Sci*. 2013;14(3):5519-44.
30. Can A, Karahuseyinoglu S. Concise review: human umbilical cord stroma with regard to the source of fetus-derived stem cells. *Stem Cells*. 2007;25(11):2886-95.
31. Mamede AC, Carvalho MJ, Abrantes AM, Laranjo M, Maia CJ, Botelho MF. Amniotic membrane: from structure and functions to clinical applications. *Cell Tissue Res*. 2012;349(2):447-58.
32. Takaoka K, Hamada H. Cell fate decisions and axis determination in the early mouse embryo. *Development*. 2012;139(1):3-14.
33. Miki T. Amnion-derived stem cells: in quest of clinical applications. *Stem Cell Res Ther*. 2011;2(3):25.
34. Dunnebacke TH, Zitcer EM. Preparation and cultivation of primary human amnion cells. *Cancer Res*. 1957;17(11):1043-6.
35. Bilic G, Zeisberger SM, Malik AS, Zimmermann R, Zisch AH. Comparative characterization of cultured human term amnion epithelial and mesenchymal stromal cells for application in cell therapy. *Cell Transpl*. 2008;17(8):955-68.
36. Kim J, Kang HM, Kim H, et al. Ex vivo characteristics of human amniotic membrane-derived stem cells. *Cloning Stem Cells*. 2007;9(4):581-94.
37. Miki T, Lehmann T, Cai H, Stolz DB, Strom SC. Stem cell characteristics of amniotic epithelial cells. *Stem Cells*. 2005;23(10):1549-59.
38. Sakuragawa N, Thangavel R, Mizuguchi M, Hirasawa M, Kamo I. Expression of markers for both neuronal and glial cells in human amniotic epithelial cells. *Neurosci Lett*. 1996;209(1):9-12.
39. Venkatachalam S, Palaniappan T, Jayapal PK, Neelamegan S, Rajan SS, Muthiah VP. Novel neurotrophic factor secreted by amniotic epithelial cells. *Biocell*. 2009;33(2):81-9.
40. Yang XX, Xue SR, Dong WL, Kong Y. Therapeutic effect of human amniotic epithelial cell transplantation into the lateral ventricle of hemiparkinsonian rats. *Chin Med J (Engl)*. 2009;122(20):2449-54.
41. Pratama G, Vaghjiani V, Tee JY, et al. Changes in culture expanded human amniotic epithelial cells: implications for potential therapeutic applications. *PLoS One*. 2011;6(11):e26136.
42. Miki T, Marongiu F, Dorko K, Ellis EC, Strom SC. Isolation of amniotic epithelial stem cells. *Curr Protoc Stem Cell Biol*. 2010;Chapter 1:Unit 1E.3.
43. Tachibana M, Amato P, Sparman M, et al. Human embryonic stem cells derived by somatic cell nuclear transfer. *Cell*. 2013;153(6):1228-38.
44. Gavrillov S, Marolt D, Douglas NC, et al. Derivation of two new human embryonic stem cell lines from nonviable human embryos. *Stem Cells Int*. 2011;2011:765378.
45. Murphy S, Rosli S, Acharya R, et al. Amnion epithelial cell isolation and characterization for clinical use. *Curr Protoc Stem Cell Biol*. 2010;Chapter 1:Unit 1E.6.
46. Whittle WL, Gibb W, Challis JR. The characterization of human amnion epithelial and mesenchymal cells: the cellular expression, activity and glucocorticoid regulation of prostaglandin output. *Placenta*. 2000;21(4):394-401.
47. Miki T, Mitamura K, Ross MA, Stolz DB, Strom SC. Identification of stem cell marker-positive cells by immunofluorescence in term human amnion. *J Reprod Immunol*. 2007;75(2):91-6.
48. Bibikova M, Laurent LC, Ren B, Loring JF, Fan JB. Unraveling epigenetic regulation in embryonic stem cells. *Cell Stem Cell*. 2008;2(2):123-34.
49. Chambers I, Tomlinson SR. The transcriptional foundation of pluripotency. *Development*. 2009;136(14):2311-22.
50. Hammer A, Hutter H, Blaschitz A, et al. Amnion epithelial cells, in contrast to trophoblast cells, express all classical HLA class I molecules together with HLA-G. *Am J Reprod Immunol*. 1997;37(2):161-71.
51. Thatte S, Gupta L. Amniotic membrane transplantation in surgically induced necrotizing scleritis with peripheral ulcerative keratitis. *Middle East Afr J Ophthalmol*. 2012;19(4):419-21.
52. Clare G, Suleman H, Bunce C, Dua H. Amniotic membrane transplantation for acute ocular burns. *Cochrane Database Syst Rev*. 2012;9:CD009379.
53. Tamagawa T, Ishiwata I, Saito S. Establishment and characterization of a pluripotent stem cell line derived from human amniotic membranes and initiation of germ layers in vitro. *Hum Cell*. 2004;17(3):125-30.
54. Grueterich M, Espana EM, Tseng SC. Ex vivo expansion of limbal epithelial stem cells: amniotic membrane serving as a stem cell niche. *Surv Ophthalmol*. 2003;48(6):631-46.
55. Rendal-Vazquez ME, San-Luis-Verdes A, Yebra-Pimentel-Vilar MT, et al. Culture of limbal stem cells on human amniotic membrane. *Cell Tissue Bank*. 2012;13(3):513-9.
56. Chen YF, Dong Z, Jiang L, Lai D, Guo L. Mouse primed embryonic stem cells could be maintained and reprogrammed on human amnion epithelial cells. *Stem Cells Dev*. 2013;22(2):320-9.
57. Liu T, Cheng W, Huang Y, Huang Q, Jiang L, Guo L. Human amniotic epithelial cell feeder layers maintain human iPS cell pluripotency via inhibited endogenous microRNA-145 and increased Sox2 expression. *Exp Cell Res*. 2012;318(4):424-34.
58. Anchan RM, Quaas P, Gerami-Naini B, et al. Amniocytes can serve a dual function as a source of iPS cells and feeder layers. *Hum Mol Genet*. 2011;20(5):962-74.
59. Liu T, Guo L, Liu Z, Cheng W. Human amniotic epithelial cells maintain mouse spermatogonial stem cells in an undifferentiated state due to high leukemia inhibitor factor (LIF) expression. *In Vitro Cell Dev Biol Anim*. 2011;47(4):318-26.
60. Liu T, Huang Y, Huang Q, Jiang L, Guo L, Liu Z. Use of human amniotic epithelial cells as a feeder layer to support undifferentiated growth of mouse spermatogonial stem cells via epigenetic regulation of the Nanog and Oct-4 promoters. *Acta Biol Hung*. 2012;63(2):167-79.
61. Lai D, Cheng W, Liu T, Jiang L, Huang Q, Liu T. Use of human amnion epithelial cells as a feeder layer to support undifferentiated growth of mouse embryonic stem cells. *Cloning Stem Cells*. 2009;11(2):331-40.
62. Hao Y, Ma DH, Hwang DG, Kim WS, Zhang F. Identification of antiangiogenic and antiinflammatory proteins in human amniotic membrane. *Cornea*. 2000;19(3):348-52.
63. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. *J Cell Physiol*. 1999;179(3):325-35.
64. King AE, Paltoo A, Kelly RW, Sallanave JM, Bocking AD, Challis JR. Expression of natural antimicrobials by human placenta and fetal membranes. *Placenta*. 2007;28(2-3):161-9.
65. Akle CA, Adinolfi M, Welsh KI, Leibowitz S, McColl I. Immunogenicity of human amniotic epithelial cells after transplantation into volunteers. *Lancet*. 1981;2(8254):1003-5.
66. Hunt JS, Petroff MG, McIntire RH, Ober C. HLA-G and immune tolerance in pregnancy. *FASEB J*. 2005;19(7):681-93.
67. Koizumi NJ, Inatomi TJ, Sotozono CJ, Fullwood NJ, Quantock AJ, Kinoshita S. Growth factor mRNA and protein in preserved human amniotic membrane. *Curr Eye Res*. 2000;20(3):173-7.
68. Jaenisch R, Young R. Stem cells, the molecular circuitry of pluripotency and nuclear reprogramming. *Cell*. 2008;132(4):567-82.
69. Raisanen S, Gissler M, Saari J, Kramer M, Heinonen S. Contribution of risk factors to extremely, very and moderately preterm births - register-based analysis of 1,390,742 singleton births. *PLoS One*. 2013;8(4):e60660.
70. Minas V, Mylonas I, Schiessl B, et al. Expression of the blood-group-related antigens Sialyl Lewis x, Sialyl Lewis y and Lewis y in term placentas of normal, preeclampsia, IUGR- and HELLP-complicated pregnancies. *Histochem Cell Biol*. 2007;128(1):55-63.
71. Parolini O, Alviano F, Bagnara GP, et al. Concise review: isolation and characterization of cells from human term placenta: outcome of the first international Workshop on Placenta Derived Stem Cells. *Stem Cells*. 2008;26(2):300-11.
72. Banas RA, Trumpower C, Bentlejewski C, Marshall V, Sing G, Zeevi A. Immunogenicity and immunomodulatory effects of amnion-derived multipotent progenitor cells. *Hum Immunol*. 2008;69(6):321-8.
73. Stadler G, Hennerbichler S, Lindenmair A, et al. Phenotypic shift of human amniotic epithelial cells in culture is associated with reduced osteogenic differentiation in vitro. *Cytotherapy*. 2008;10(7):743-52.
74. Fatimah SS, Ng SL, Chua KH, Hayati AR, Tan AE, Tan GC. Value of human amniotic epithelial cells in tissue engineering for cornea. *Hum Cell*. 2010;23(4):141-51.
75. Maguire CT, Demarest BL, Hill JT, et al. Genome-wide analysis reveals the unique stem cell identity of human amniocytes. *PLoS One*. 2013;8(1):e53372.
76. Marongiu F, Gramignoli R, Dorko K, et al. Hepatic differentiation of amniotic epithelial cells. *Hepatology*. 2011;53(5):1719-29.
77. Fang CH, Jin J, Joe JH, et al. In vivo differentiation of human amniotic epithelial cells into cardiomyocyte-like cells and cell transplantation effect on myocardial infarction in rats: comparison with cord blood and adipose tissue-derived mesenchymal stem cells. *Cell Transplant*. 2012;21(8):1687-96.